

Anne Sophie ChrÃ©tien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9424409/publications.pdf>

Version: 2024-02-01

21
papers

628
citations

471509

17
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

1060
citing authors

#	ARTICLE	IF	CITATIONS
1	Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. <i>Nature Communications</i> , 2022, 13, .	12.8	45
2	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
3	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	3.3	25
4	Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study. <i>Blood</i> , 2021, 138, 1817-1817.	1.4	5
5	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019, 8, 1615818.	4.6	34
6	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2019, 8, e1561120.	4.6	92
7	Anti-BTN3A 20.1 Agonist Monoclonal Antibody Enhances Autologous VÎ³9VÎ²2 T Cells Cytotoxicity Against Primary Acute Myeloid Blasts. <i>Blood</i> , 2019, 134, 5153-5153.	1.4	4
8	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>Oncolmmunology</i> , 2017, 6, e1307491.	4.6	37
9	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2017, 77, 6627-6640.	0.9	23
10	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 573.	4.8	47
11	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 49548-49563.	1.8	34
12	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 94.	4.8	26
13	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 564.	4.8	24
14	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	4.8	75
15	Human plasmacytoid dendritic cells regulate IFN-Î± production through activation-induced splicing of IL-18RÎ±. <i>Journal of Leukocyte Biology</i> , 2014, 96, 1037-1046.	3.3	4
16	Using one-step nucleic acid amplification (OSNA) for intraoperative detection of lymph node metastasis in breast cancer patients avoids second surgery and accelerates initiation of adjuvant therapy. <i>Annals of Oncology</i> , 2013, 24, 2305-2309.	1.2	25
17	Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line targeted therapy selection in metastatic colorectal cancer. <i>Cancer Medicine</i> , 2013, 2, 11-20.	2.8	18
18	Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line. <i>International Journal of Oncology</i> , 2010, 37, 1555-63.	3.3	11

#	ARTICLE	IF	CITATIONS
19	Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer. <i>Clinical Chemistry</i> , 2009, 55, 1327-1336.	3.2	18
20	P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. <i>Cancer Gene Therapy</i> , 2009, 16, 498-507.	4.6	19
21	PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. <i>Oncology Reports</i> , 2009, 21, 731-5.	2.6	33